Current therapies for AD, such as acetyl cholinesterase (AChE) inhibitors and N-methyl-D-aspartate receptor (NMDAR) antagonists, afford only temporary symptomatic relief without modifying disease progression long term. The gene discussed is ACHE; the disease is Alzheimer disease.